Open an account

Alto Neuroscience

ANRO · NYSE

$24.41+$1.59 (+6.97%)TodayMarket closed ·
Prev close $22.82

About ANRO

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. The company is headquartered in Mountain View, California and currently employs 68 full-time employees. The company went IPO on 2024-02-02. The firm's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

Employees
68
Headquarters
Mountain View, California
Listed
Feb 2, 2024
Sector
Health Care
Industry
Pharmaceuticals
Website
altoneuroscience.com

ANRO key statistics

Market cap
957.90M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
655.98K
Volume
869.41K
Open price
$23.23
High today
$24.91
Low today
$23.02
52 Week high
$37.48
52 Week low
$6.72

Alto Neuroscience (ANRO) at a glance

As of Oct 20, 2026, Alto Neuroscience (ANRO) shares are priced at $24.41, giving the company a market cap of 957.90M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $23.02 and $24.91. The current price is 6.0% above the day's low and 2.0% below its high.

Volume so far is 869.41K shares, above the average of 655.98K shares a day.

Over the past year Alto Neuroscience has ranged from $6.72 to $37.48, and now sits 58% of the way up that range.

Alto Neuroscience met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.65 per share against an estimate of -$0.7492.

The average analyst price target is $38.87, 59.3% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

86%of 7 analyst ratings say Buy
  • Buy85.7%
  • Hold14.3%
  • Sell0.0%
Price target · 11 analystsAvg $38.87
Low
$26.26
Now
$24.41
High
$57.75

ANRO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 13.8% on average.

  1. Q3 FY24: reported -$0.62 per share against an estimate of -$0.6664
  2. Q4 FY24: reported -$0.56 per share against an estimate of -$0.663
  3. Q1 FY25: reported -$0.56 per share against an estimate of -$0.6202
  4. Q2 FY25: reported -$0.65 per share against an estimate of -$0.6253
  5. Q3 FY25: reported -$0.52 per share against an estimate of -$0.6811
  6. Q4 FY25: reported -$0.58 per share against an estimate of -$0.5414
  7. Q1 FY26: reported -$0.80 per share against an estimate of -$0.5473
  8. Q2 FY26: reported -$0.65 per share against an estimate of -$0.7492

ANRO news

  • Press releaseBusiness Wire

    Alto Neuroscience Announces Participation in Upcoming Investor Conferences

  • Press releaseBusiness Wire

    Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

  • Press releaseBusiness Wire

    Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

  • Press releaseBusiness Wire

    Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

  • Press releaseBusiness Wire

    Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

  • Press releaseBusiness Wire

    Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

  • Press releaseBusiness Wire

    Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

  • Press releaseBusiness Wire

    Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

Similar companies

Companies in the same industry as Alto Neuroscience

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.